MRC1 and cystic fibrosis: NE has been shown to proteolytically target immune cell surface proteins in CF and COPD patients including CD40, CD80, and CD86 on dendritic cells [14], CD2, CD4, and CD8 on T cells [15], and CD14, CD206, and CD44 on human BMDMs [16,17].